The US Food and Drug Administration expanded its approval of tildrakizumab-asmn, an interleukin-23 inhibitor administered by healthcare providers, to include adults with active psoriatic arthritis.
The US Food and Drug Administration expanded its approval of tildrakizumab-asmn, an interleukin-23 inhibitor administered by healthcare providers, to include adults with active psoriatic arthritis.
Key Clinical Summary
A multicenter Italian real-world study of 868 patients with psoriatic arthritis found durable long-term retention of interleukin-17 (IL-17) inhibitors, with overall retention of 77.5% at 12 months and 52.1% at 36...
Key Clinical Summary
A multicenter Italian real-world study of 868 patients with psoriatic arthritis found durable long-term retention of interleukin-17 (IL-17) inhibitors, with overall retention of 77.5% at 12 months and 52.1% at 36...
Key Clinical Summary
A...
07/23/2026
Rheumatology & Arthritis
About Us
Rheumatology and Arthritis Learning Network® is an online resource for the latest developments in rheumatology practice, providing a customized experience for readers to stay informed about the topics that matter most to them.
